BERLIN and SEATTLE, April 14, 2008 (PRIME NEWSWIRE) -- Epigenomics AG (Frankfurt Prime Standard: ECX), a molecular diagnostics company focusing on the development and commercialization of in-vitro diagnostic tests for cancer, updates on its program for the development of test for prostate cancer screening and diagnosis. The company presented recent data at this year's Annual Meeting of the American Association for Cancer Research (AACR) in San Diego, USA.
